

REMARKS/ARGUMENTS

The Restriction action dated 4 January 2006 required election between claim groups I-IV. Applicants herein elect claim group III, including claims 6-13, drawn to a method of inhibiting pain or nociceptin with an agent capable of modulating NMUR2 activity. Accordingly, non-elected claims 1-5 and 14-16 are cancelled without prejudice or disclaimer.

Claim group III is subject to a species elections for initial search purposes. Applicants elect chronic pain resulting from injury to the body. Claims 6-13 read upon the elected species.


Conclusion

It is believed that this document is fully responsive to the Restriction requirement raised in the Restriction action dated 4 January 2006. In light of the above amendments and remarks, it is believed that the claims are now in condition for allowance, and such action is respectfully urged.

Fees

It is believed that no fee is due with the submission of this response. In the event it is determined that a fee is due, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650 for the amount of that fee.

Respectfully submitted


Valeta Gregg, Ph.D., Reg. No. 35,127
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 593-1077 (direct)